DR. DAVID H BARAD, M.D.
Medical Practice at 69 St, New York, NY

2006008, Apr 27, 2006

Nov 8, 2005

11/269310

Norbert Gleicher - Chicago IL, US
David Barad - Closter NJ, US
Dwyn Harben - Bryn Mawr PA, US

A61K 31/56

514170000, 800021000

A method of improving cumulative embryo score may comprise administering an androgen to a human female, for example, DHEA, for at least about four consecutive months followed by harvesting and fertilizing oocytes and forming embryos. Between about 50 mg and about 100 mg of DHEA may be administered to a human female per day. Moreover, a method of increasing the quantity of fertilized oocytes in one cycle of in vitro fertilization may comprise administering an androgen to a human female for at least about four consecutive months, harvesting and fertilizing the oocytes. Furthermore, a method of increasing the quantity of day 3 embryos from one cycle of in vitro fertilization may comprise administering an androgen for at least about four consecutive months, harvesting and fertilizing the oocytes and forming day 3 embryos. A method of normalizing ovarian DHEA also may include administering an androgen for at least about four consecutive months. A method of increasing the euploidy rate in embryos may include administering an androgen for at least about four consecutive weeks.

2007015, Jul 5, 2007

Mar 1, 2007

11/680973

Norbert GLEICHER - Chicago IL, US
David Barad - Closter NJ, US
Dwyn Harben - Bryn Mawr PA, US

A61K 31/57

514177000

A method of improving cumulative embryo score may comprise administering an androgen to a human female, for example, DHEA, for at least about four consecutive months followed by harvesting and fertilizing oocytes and forming embryos. Between about 50 mg and about 100 mg of DHEA may be administered to a human female per day. Moreover, a method of increasing the quantity of fertilized oocytes in one cycle of in vitro fertilization may comprise administering an androgen to a human female for at least about four consecutive months, harvesting and fertilizing the oocytes. Furthermore, a method of increasing the quantity of day 3 embryos from one cycle of in vitro fertilization may comprise administering an androgen for at least about four consecutive months, harvesting and fertilizing the oocytes and forming day 3 embryos. A method of normalizing ovarian DHEA also may include administering an androgen for at least about four consecutive months. A method of increasing the rate and number of euploid oocytes may include administering an androgen for at least about four consecutive weeks. In addition, a method of increasing male fetus sex ratio may comprise raising baseline androgen levels in a female prior to or at time of embryo implantation.

2011002, Jan 27, 2011

Jul 23, 2009

12/508295

Norbert GLEICHER - Chicago IL, US
David H. BARAD - Closter NJ, US

C12Q 1/68

435 6

A method of predicting a degree of risk of early ovarian aging of a young female. The method includes analyzing the female's FMR1 gene, wherein the FMR1 gene has a first allele and a second allele; determining the number of triple CGG repeats on each of the first and second alleles; defining a normal range of triple CGG repeats; comparing the number of triple CGG repeats on each of the first and second alleles to the normal range. If the triple CGG repeat numbers for both of the first and second alleles are within the normal range, then the female is at minimal risk for early ovarian aging. If the triple CGG repeat number for one of the first and second alleles is outside of the normal range and the other one of the first and second alleles is within the normal range, then the first and second alleles are heterozygous and the female is at increased risk for early ovarian aging. If the triple CGG repeat numbers for both of the first and second alleles are outside of the normal range, then the first and second alleles are homozygous and the female is also at an increased risk for early ovarian aging.

2011015, Jun 30, 2011

Mar 8, 2011

13/043199

Norbert GLEICHER - Chicago IL, US
David H. Barad - Closter NJ, US

C12Q 1/68

435 611

A method of predicting a degree of risk of autoimmunity in a human female is disclosed. The method may include analyzing the female's FMR1 gene, wherein the FMR1 gene has a first allele and a second allele, determining the number of triple CGG repeats on each of the first and second alleles; defining a normal range of triple CGG repeats; and comparing the number of triple CGG repeats on each of the first and second alleles to the normal range. If the triple CGG repeat number for one of the first and second alleles is in the normal range and the triple CGG repeat number for the other one of the first and second alleles is less than the lower boundary of the normal range, then the female is at increased risk of autoimmunity. Additionally, a method of predicting pregnancy chances for a human female is disclosed. The method may include analyzing the female's FMR1 gene, wherein the FMR1 gene has a first allele and a second allele; determining the number of triple CGG repeats on each of the first and second alleles; defining a normal range of triple CGG repeats; and comparing the number of triple CGG repeats on each of the first and second alleles to the normal range. If the triple CGG repeat number for one of the first and second alleles is in the normal range and the triple CGG repeat number for the other one of the first and second alleles is less than the lower boundary of the normal range, then the female has decreased chances of pregnancy.

8067400, Nov 29, 2011

May 20, 2008

12/123877

Norbert Gleicher - Chicago IL, US
David H. Barad - Closter NJ, US
Dwyn V. Harben - Bryn Mawr PA, US

American Infertility of New York - New York NY

A61K 31/56, A61P 15/08, A61K 31/5685

514170, 514169

A method of improving cumulative embryo score may comprise administering an androgen to a human female for at least about four consecutive months followed by harvesting and fertilizing oocytes and forming embryos. A method of increasing the quantity of fertilized oocytes in one cycle of in vitro fertilization may comprise administering an androgen to a human female for at least about four consecutive months, harvesting and fertilizing the oocytes. A method of normalizing ovarian DHEA may include administering an androgen for at least about four consecutive months. A method of decreasing the time to pregnancy and increasing the rate of pregnancy by administering an androgen for at least about two months. A method of decreasing miscarriage rates may comprise administering an androgen for at least about two months to a female. Moreover, a method of decreasing aneuploidy rates in human embryos may comprise administering an androgen to a female for at least about two months.

2011020, Aug 25, 2011

Mar 8, 2011

13/043266

Norbert Gleicher - Chicago IL, US
David H. Barad - Closter NJ, US

A61K 31/566, A61P 15/08, C12Q 1/68

514179, 435 61, 435 611

The present invention is directed to a method of using dehydroepiandrosterone to treat a human female with diminished ovarian reserve. The method includes administering about 25 milligrams three times a day of dehydroepiandrosterone per day to the female for at least four weeks to reduce human embryo aneuploidy. The present invention further is directed to a method of treating a human female with diminished ovarian reserve to improve the female's diminished ovarian reserve.

2012012, May 24, 2012

Jan 27, 2012

13/360349

Norbert GLEICHER - Chicago IL, US
David H. BARAD - Closter NJ, US

A61K 47/46, A61P 35/00, C12Q 1/68

514789, 435 612

A method of screening a human for risk of malignancies is disclosed. The method may include isolating the human's FMR1 gene, wherein the FMR1 gene has a first allele and a second allele, measuring the number of triple CGG repeats on each of the first and second alleles, wherein the measuring step is conducted through use of an assay, and identifying the human as at risk for cancer when the triple CGG repeat number for at least one of the first and second alleles is less than 26.

8501718, Aug 6, 2013

Oct 7, 2009

12/575426

Norbert Gleicher - Chicago IL, US
David H. Barad - Closter NJ, US
Dwyn V. Harben - Bryn Mawr PA, US

American Infertility of New York - New York NY

A01N 45/00, A61K 31/56

514169, 514177

The present invention is directed to a method of improving ovarian reserve in a human female with diminished ovarian reserve as measured by the female's anti-Müllerian hormone level. The method may include evaluating a first anti-Müllerian hormone level of the female, administering dehydroepiandrosterone to the female for at least about one month, and evaluating a second anti-Müllerian hormone level of the female, wherein the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level.